SinoCellTech
An innovative biopharmaceutical company in Beijing, China, focused on monoclonal antibodies, recombinant proteins, and vaccines.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
SinoCellTech is an innovative biopharmaceutical company founded by Dr. Xie Liangzhi, specializing in the R&D and industrialization of biological drugs such as monoclonal antibodies, recombinant proteins, and vaccines. The company was established in 2002 and is headquartered in Beijing Economic-Technological Development Area. It has multiple products launched in China and a pipeline of clinical candidates.
History
SinoCellTech was founded in 2002. The company is led by Dr. Xie Liangzhi, an expert in biopharmaceutical R&D and industrialization. It focuses on monoclonal antibodies, recombinant proteins, and vaccines. In 2020, the company went public on the Shanghai Stock Exchange STAR Market. The company has developed products for diseases such as hemophilia, cancer, autoimmune diseases, and infectious diseases.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sinocelltech · Editorial policy · How profiles are compiled